Influenza revenues rose 112 percent due to an especially long and severe respiratory disease season, dominated by a virulent H3N2 strain of influenza.
The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.
The firm also announced a CE mark and pending commercial release for a FilmArray Respiratory Panel test for 22 pathogens responsible for respiratory tract infections.
The company beat Wall Street analysts' expectations for sales and earnings per share during the quarter.
The company beat the consensus Wall Street estimates on both the top and bottom lines. It also increased its EPS outlook for full-year 2017.
Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition.
Interleukin said the reduction in revenues resulted from lower contract research revenue and fewer kits returned for processing related to a promotional product bundle program.
The firm said that certain financial statements stretching back to 2013 are unreliable because of misconduct at Standard Diagnostics, its South Korean subsidiary.
The company attributed the decline in part to nonrecurring sales of its Unyvero molecular diagnostic system to partners for clinical trials and regulatory clearances.
The firm, which is the target of several lawsuits connected with its IPO, said 452 GPS Cancer Tests were ordered during the quarter.